Podcasts about Arc

This week on the Missouri Woods & Water Podcast, Wade Chandler discusses the intricacies of predator hunting, focusing on the best rifle choices for coyote hunting.  The conversation delves into the advantages and disadvantages of various cartridges, particularly the 6 ARC and 22 ARC, and the importance of bullet performance and shot placement.  Wade emphasizes the evolution of ammunition technology and the significance of understanding gear to enhance hunting success.  The episode also touches on practical hunting scenarios, the future of ammunition technology, and the versatility of the AR-15 platform.     Takeaways  Choosing the right rifle depends on personal comfort and experience. The 6 ARC and 22 ARC are popular choices for coyote hunting. Factory ammo availability can influence cartridge selection. Shot placement is crucial for effective hunting. Modern cartridges offer better performance than legacy options. Twist rates in barrels affect bullet accuracy and performance. Thermal hunting requires different considerations than daytime hunting. The AR-15 platform allows for versatility in hunting setups. Practice is essential for successful hunting outcomes. Future advancements in ammunition technology will enhance hunting effectiveness.   Check out the MWW Website for shows, partner discounts, and more!!! Subscribe To Our YouTube Channel!!! HUXWRX Athlon Optics Midwest Gun Works Lucky Buck OnX  Use code MWW20 for 20% off  Camofire Black Ovis:  Use code MWW10 for 10% off Reveal Cameras by Tactacam Jason Patterson Land Team - Whitetail Properties 816-824-6282 jason.patterson@whitetailproperties.com Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on the Missouri Woods & Water Podcast, Wade Chandler discusses the intricacies of predator hunting, focusing on the best rifle choices for coyote hunting.  The conversation delves into the advantages and disadvantages of various cartridges, particularly the 6 ARC and 22 ARC, and the importance of bullet performance and shot placement.  Wade emphasizes the evolution of ammunition technology and the significance of understanding gear to enhance hunting success.  The episode also touches on practical hunting scenarios, the future of ammunition technology, and the versatility of the AR-15 platform.  Takeaways Choosing the right rifle depends on personal comfort and experience.The 6 ARC and 22 ARC are popular choices for coyote hunting.Factory ammo availability can influence cartridge selection.Shot placement is crucial for effective hunting.Modern cartridges offer better performance than legacy options.Twist rates in barrels affect bullet accuracy and performance.Thermal hunting requires different considerations than daytime hunting.The AR-15 platform allows for versatility in hunting setups.Practice is essential for successful hunting outcomes.Future advancements in ammunition technology will enhance hunting effectiveness. Check out the MWW Website for shows, partner discounts, and more!!!Subscribe To Our YouTube Channel!!!HUXWRXAthlon OpticsMidwest Gun WorksLucky BuckOnX  Use code MWW20 for 20% off CamofireBlack Ovis:  Use code MWW10 for 10% offReveal Cameras by TactacamJason Patterson Land Team - Whitetail Properties816-824-6282jason.patterson@whitetailproperties.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week on the Missouri Woods & Water Podcast, Wade Chandler discusses the intricacies of predator hunting, focusing on the best rifle choices for coyote hunting.  The conversation delves into the advantages and disadvantages of various cartridges, particularly the 6 ARC and 22 ARC, and the importance of bullet performance and shot placement.  Wade emphasizes the evolution of ammunition technology and the significance of understanding gear to enhance hunting success.  The episode also touches on practical hunting scenarios, the future of ammunition technology, and the versatility of the AR-15 platform.   Takeaways Choosing the right rifle depends on personal comfort and experience.The 6 ARC and 22 ARC are popular choices for coyote hunting.Factory ammo availability can influence cartridge selection.Shot placement is crucial for effective hunting.Modern cartridges offer better performance than legacy options.Twist rates in barrels affect bullet accuracy and performance.Thermal hunting requires different considerations than daytime hunting.The AR-15 platform allows for versatility in hunting setups.Practice is essential for successful hunting outcomes.Future advancements in ammunition technology will enhance hunting effectiveness. Check out the MWW Website for shows, partner discounts, and more!!!Subscribe To Our YouTube Channel!!!HUXWRXAthlon OpticsMidwest Gun WorksLucky BuckOnX  Use code MWW20 for 20% off CamofireBlack Ovis:  Use code MWW10 for 10% offReveal Cameras by TactacamJason Patterson Land Team - Whitetail Properties816-824-6282jason.patterson@whitetailproperties.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textLaurie Show was a 16-year-old high school student from Lancaster, Pennsylvania, whose life was tragically cut short in 1991 in a brutal act of jealousy and revenge. She had briefly dated an older teen, Lawrence  Yunkin, who was in a volatile relationship with another teenager, Michelle Lambert. Lambert became increasingly obsessed with harassing and threatening Laurie. On the morning of December 20, 1991, Laurie was attacked and murdered in her home by Lambert and her friend Tabitha Buck. The horrifying case gained national attention and led to lengthy trials, appeals, and changes in Pennsylvania's anti-stalking laws, largely due to the advocacy of Laurie's mother, Hazel Show. In 2000, Lifetime adapted the story into a made-for-TV film titled The Stalking of Laurie Show, dramatizing the events leading up to Laurie's death. Sources:Overkill by Lyn Riddle The Stalking of Laurie Show https://www.youtube.com/watch?v=YCwRY0qffDIhttps://lancastercountypa.gov/CivicAlerts.aspx?AID=1008&ARC=1439https://www.youtube.com/watch?v=ItVOg2lzq4Ehttps://co.lancaster.pa.us/CivicAlerts.aspx?AID=1008&ARC=1438https://www.pennlive.com/news/2019/12/28-years-after-killing-laurie-show-teen-murderer-tabitha-buck-is-bound-for-freedom.htmlhttps://www.wgal.com/article/wgal-becomes-courtroom-for-appeal-by-convicted-killer-lisa-michelle-lambert/60178594*This podcast is independently produced using publicly available information and personal research. I approach each story with care and respect, though I recognize that I may not always have access to every voice or perspective involved. If you're connected to the story and would like to share your experience, I truly welcome the opportunity to include your insights in a future update. Email Residue: residuepodcast@gmail.comFind RESIDUE online:Instagram: @residuepodcastTik Tok: @residuepodcast Facebook: Residue:A True Crime Podcast Credits: RESIDUE is Hosted/Produced/Researched/Edited by Chrissy Champagne THEME SONG: "Dance Of Death" by Purple Planet Music collection written and performed by Chris Martyn and Geoff Harvey. Additional music provided by Epidemic Sound. Residue logo designed by Tricia Cappelli

"Developing a Relationship with God Through Prayer" | Rev. Sam Howard | 9.15.25 by ARC of Carson City, NV

In this fifth episode of the Special Chronicles Podcast LIVE Coverage, host Daniel Smrokowski talks with Nicholas T from Envision Unlimited. We're excited to announce that Special Chronicles provided exclusive LIVE and On-Demand Coverage of the The Arc of Illinois #SUSO2025 – the annual Speak Up and Speak Out Summit that celebrates the voices of people with disabilities. You'll hear directly from disability self-advocates, families, speakers, and professionals as they share their voices on leadership, advocacy, and inclusion. This annual self-advocacy conference empowers people with disabilities to speak up for themselves, take action, and create positive change in their communities. Let's Speak Up. Let's Speak Out. Let's Be Heard. Join The Conversation

A/V industry expert and custom integrator John Sciacca joins the eCoustics team to break down our top picks from CEDIA Expo 2025, held September 3–6. The annual trade show covers everything from home theater and soundbars to architectural speakers and outdoor A/V systems—gear designed for the pros who install and recommend solutions for luxury homes and yachts. We'll highlight this year's “Best in Show” winners across multiple categories—and call out a few products that didn't quite live up to the hype.Panel:John Sciacca, Partner at Custom Theater and AudioChris Boylan, eCoustics Editor-at-LargeRobert Silva, eCoustics Sr. News CorrespondentBrian Mitchell, eCoustics Founder and HostThank you to Marantz and SVS for their support of our programming!www.svsound.comwww.marantz.comCredits:• Original intro music by The Arc of All. https://sourceoflightandpower.bandcamp.com• Voice Over Provided by Todd Harrell of SSP Unlimited. https://sspunlimited.com• Production by Mitch Anderson, Black Circle Studios. https://blackcircleradio.comDon't forget to check our website for daily updates on the latest electronics, news, recommendations, and deals on high-end audio, loudspeakers, earphones, TVs, and more.www.ecoustics.com#cedia2025 #ecoustics #hifi #audiophile #hometheater #avtech #custominstall #bestof2025tech #musicindustry #projectors #dolbyatmos #bestsoundbar #besttv #beststereo

Can we make science as fast as software? In this episode, Erik Torenberg talks with Patrick Hsu (cofounder of Arc Institute) and a16z general partner Jorge Conde about Arc's “virtual cells” moonshot, which uses foundation models to simulate biology and guide experiments. They discuss why research is slow, what an AlphaFold-style moment for cell biology could look like, and how AI might improve drug discovery. The conversation also covers hype versus substance in AI for biology, clinical bottlenecks, capital intensity, and how breakthroughs like GLP-1s show the path from science to major business and health impact. Resources:Find Patrick on X: https://x.com/pdhsuFind Jorge on X: https://x.com/JorgeCondeBio Stay Updated:Find a16z on XFind a16z on LinkedInListen to the a16z Podcast on SpotifyListen to the a16z Podcast on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Emmet Kennedy is joined by Adam Mills (Total Performance Data), Georgia Cox, and Jamie Wrenn to break down a weekend of drama, controversy, and potential Classic stars from Doncaster, Leopardstown, and the Curragh.

Melody Johnson, Director of Education and Professional Development at Arc of Monroe, shares her personal and professional journey in the field of intellectual and developmental disabilities (IDD). Growing up in a family that provided care for individuals transitioning out of institutions, Melody was deeply influenced by her mother's progressive approach to fostering independence. Her career evolved from direct support professional (DSP) roles to leadership in workforce transformation and training. She discusses how COVID-19 reshaped training delivery, increasing accessibility through virtual platforms while also highlighting the trauma and isolation experienced by people with disabilities. Melody emphasizes the importance of trauma-informed care, shifting perspectives from “what's wrong with you” to “what happened to you.” She shares meaningful stories from her time as a DSP, including organizing enriching trips for individuals she supported. In her closing advice, she encourages inclusive community interactions, early exposure for children to diverse environments, and recognizes the deeply rewarding nature of working in the IDD field—not as a calling for angels, but for those who care.

In this heartwarming episode of the Special Chronicles Podcast, host Daniel Smrokowski is joined by United Airlines Captain Tait Wasser to reflect on the powerful impact of The Arc's Wings for All event held on August 16, 2025, at Chicago O'Hare International Airport (ORD). Captain Tait shares what it was like to participate in this inclusive airport rehearsal program designed for individuals with autism and other intellectual/developmental disabilities. From behind-the-scenes moments to one young passenger's transformative journey from fear to flying — this episode showcases how partnerships like United's Bridge Disability Business Resource Group are helping make air travel more inclusive. Together, we dive into what inclusion means in the skies, the training and empathy required to support all travelers, and how we can all play a role in making the world more accessible.

Chrome 的時代即將終結？AI 正在改寫你的上網體驗！過去數十年，Chrome 幾乎是瀏覽器的代名詞，穩坐網路入口的霸主地位。但現在，一股強大的 AI 浪潮正從四面八方席捲而來，預示著一場前所未有的瀏覽器大戰！Google 剛剛才在反壟斷案中驚險過關，Chrome 卻意外免於拆分？ 與此同時，Perplexity Comet 以最強 AI 代理模式迅速圈粉，Atlassian 更豪擲 6.1 億美金，賭上一切要重新定義「知識工作者」的瀏覽器，連 OpenAI 都準備加入戰局！瀏覽器，這個你每天開啟無數次的應用，不再只是上網工具，它將成為你專屬的 AI 大腦！這集我們就來聊聊：

Listen to weekly sermons from Velocity Church in Lawrence, KS. Velocity is a vision-fueled and faith-filled community changing lives and transforming a city with the message of Jesus. For more information visit www.findvelocity.org

"The Difference is the Power" | Rev. Sam Howard | 9.14.25 by ARC of Carson City, NV

Cesky and Hurinfan discuss Josiah Bancroft's new Hexologists story, A Tangle of Time and we go into full spoilers.Disclaimer: Green Team received an ARC of The Hexologists: A Tangle of Time by Josiah Bancroft courtesy of NetGalley and Orbit Books. We thank them for the early copy for review. All opinions are our own. The Hexologists: A Tangle of Time releases on September 9th, 2025. Hope you enjoy the episode.Music is Galactic Damages by Jingle Punks.Find us on:Discord: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/FNcpuuA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BlueSky: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bsky.app/profile/greenteampod.bsky.social⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Threads:⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.threads.net/@greenteampod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Reddit: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.reddit.com/r/thelegendarium/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Suggestion Box: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://forms.gle/Nsz6URWeq3JeeZnGA

Bad Bunny, or Benito Antonio Martínez Ocasio, is dominating headlines and social media this week as he wraps up his epic two-month residency, No Me Quiero Ir de Aquí, at Puerto Rico's Coliseo de Puerto Rico. This 30-concert extravaganza transformed San Juan into a nonstop celebration, drawing fans worldwide and sparking a festival atmosphere across the city—bars overflowed, murals sprang up overnight, and legendary surprise guests hit the stage. Reports from Radio Milwaukee paint a scene of San Juan “alive,” with airport lines snaking out the door for merch, pop-ups celebrating Benito, and entire neighborhoods blasting his biggest hits. Inside the arena, each performance was a spectacle of lights, pyrotechnics, Puerto Rican iconography, and star-studded cameos—Arcángel, Ivy Queen, Young Miko, and Feid all took turns electrifying the crowd.The residency was more than a concert series; it was a declaration of Puerto Rican pride and a global showcase of Latin music's power. Bad Bunny himself, sharing with i-D Magazine, described the energy as “unprecedented,” uniting generations with music rooted in salsa, bomba y plena, and classic reggaetón influences interspersed throughout his flashy pop catalog.Just this Monday, Bad Bunny surprised fans with the release of his new single “Alambre Púa.” According to AOL, he debuted the track live for the residency's closing weekend, using it as the adrenaline-charged opener that set the tone for a 30-song marathon. This marks his first new music since January's album, Debí Tirar Más Fotos, which itself remains a Billboard and streaming juggernaut well into the year. Variety notes that the album's popularity is powering everything from record sales to unique brand tie-ins, like a special Peloton workout series celebrating Bad Bunny's music and artistic journey.The residency, however, is only the beginning of Bad Bunny's next chapter. ABC News and The Fader detail that his highly anticipated world tour for 2025-2026, supporting Debí Tirar Más Fotos, will not feature any U.S. dates. Bad Bunny cited not just a sense that he had “already done the U.S. extensively,” but, more seriously, concerns about safety and the threat of ICE raids for himself and his fans—a move the artist discussed candidly with both Variety and i-D.Recognition for Bad Bunny's achievements continues to skyrocket: the Latin Times confirms that he just broke the all-time record for nominations at the 2025 Billboard Latin Music Awards, earning an incredible 27 nominations. He leads across categories—Artist of the Year, Songwriter of the Year, Top Latin Album for Debí Tirar Más Fotos, and a slew of individual single nominations, underscoring his dominance in both streaming and on the charts. The awards ceremony will air live on October 23, 2025, from Miami, so expect even more historic moments as the date approaches.Meanwhile, Bad Bunny's cultural reach goes further than music. As reported by Variety, he's starring alongside Adam Sandler in the much-hyped movie Happy Gilmore 2, released in July, continuing his rapid rise as a multifaceted global entertainer.Thanks for tuning in—come back next week for another update on Bad Bunny and all things music. This has been a Quiet Please production; for more, check out Quiet Please Dot A I.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Al fin y al cabo “los buenos” quizás no son tan buenos. El Teatro Poliorama de Barcelona acoge hasta el 2 de noviembre Els Bons. Una comedia sobre corrupción y amistad que nos presentan su director, Paco Mir, y sus protagonistas, Jordi Boixaderas y Ramón Madaula (autor además del texto).La Navidad está a punto de llegar, y dos amigos se han citado en el Círculo Artístico del pueblo, donde, desde hace años, interpretan Satanás y Arcángel Miquel en Els Pastorets. Este año, quien debía ponerse en la piel de Satanás no podrá hacerlo: acaba de perder un recurso de apelación y debe entrar en prisión. Como favor, pedirá a su gran amigo que cambie de personaje y se convierta en el rey del infierno. Los problemas surgen cuando descubren que a su sustituto le cuesta muchísimo hacer malo y que tendrá que aprender todos los trucos necesarios para despertar la maldad suficiente para ser un buen Satanás.Escuchar audio

This story isn't intended for young or sensitive readers. Readers who are on the lookout for trigger warnings are advised to give Worm a pass. Complete list of potential triggers: here-----------------------------------The Brockton Bay Book Club discusses J.C. McCrae's Ward live! The gang reads a portion of Ward and comes together to share our thoughts with each other and anyone who want's to participate.This week we cover Arc 8.1 to 8.7 - Beacon!Read along herePlay along with this week's BBBC BINGO while you listen!Support us and connect with us @brocktonbaybc-----------------------------------Thank you to the sponsors that fuel our podcast: This episode of the Brockton Bay Book Club is sponsored by Made Marion. Made Marion creates custom cottagecore and ren faire clothing designed for every body. Whether you're looking for a lace up bodice, rustic apron and pinafores, or ethereal dresses, you'll find items customized for every individual's fit and design. All items are lovingly hand sewn with attention to detail and a touch of whimsy. Visit Made Marion today and transform your wardrobe with clothing that feels as enchanting as it looks. Find Made Marion on etsy, at https://www.etsy.com/shop/themademarion

In this fourth episode of the Special Chronicles Podcast LIVE Coverage, host Daniel Smrokowski talks with Deanna E from Envision Unlimited. We're excited to announce that Special Chronicles provided exclusive LIVE and On-Demand Coverage of the The Arc of Illinois #SUSO2025 – the annual Speak Up and Speak Out Summit that celebrates the voices of people with disabilities. You'll hear directly from disability self-advocates, families, speakers, and professionals as they share their voices on leadership, advocacy, and inclusion. This annual self-advocacy conference empowers people with disabilities to speak up for themselves, take action, and create positive change in their communities. Let's Speak Up. Let's Speak Out. Let's Be Heard. Join The Conversation

"Search for Truth 65" | Pastor Evan Hood | 9.10.25 by ARC of Carson City, NV

In this third episode of the Special Chronicles Podcast LIVE Coverage, host Daniel Smrokowski talks with April McHenry and Leanne Mull who have been at the first SUSO 20 years ago. We're excited to announce that Special Chronicles provided exclusive LIVE and On-Demand Coverage of the The Arc of Illinois #SUSO2025 – the annual Speak Up and Speak Out Summit that celebrates the voices of people with disabilities. You'll hear directly from disability self-advocates, families, speakers, and professionals as they share their voices on leadership, advocacy, and inclusion. This annual self-advocacy conference empowers people with disabilities to speak up for themselves, take action, and create positive change in their communities. Let's Speak Up. Let's Speak Out. Let's Be Heard. Join The Conversation

On this episode of Waves of Awareness, we're excited to welcome Katy Clouse and Brooke Tanner from The Arc of Williamson County. The Arc has been a cornerstone in supporting individuals with intellectual and developmental disabilities, and today, you'll hear how their work continues to shape lives across the community. Host Staci Davis, alongside co-hosts Matt Moore and Johnny Sunshine, dives into the mission behind The Arc, the resources and advocacy they provide, and the impact they've seen firsthand. Katy and Brooke also pull back the curtain on what their day-to-day roles look like, plus they share details about partnerships and upcoming events you'll want to have on your radar. Before wrapping up, John and Matt share some personal life updates—including Matt's volunteer work in Williamson County—and highlight ways you can get involved in supporting The Arc's mission. ✨ If you're looking for inspiration, community connection, and a deeper understanding of disability advocacy, this conversation is for you. Press play and join us! ________________________________________ Learn more about Waves: wavesinc.com Learn more about The Arc here: https://thearcwc.org/ Watch Waves of Awareness on YouTube: @Waves_of_Awareness Get your tickets for Brews & Grooves: wavesinc.com/events Check out Spread The Positive: spreadthepositive.net

In this second episode of the Special Chronicles Podcast LIVE Coverage, host Daniel Smrokowski talk to Eva Kott and her parents Michael and Alena about her self-advocacy story, first-time speaking at this conference, and her empowering story.  We're excited to announce that Special Chronicles provided exclusive LIVE and On-Demand Coverage of the The Arc of Illinois #SUSO2025 – the annual Speak Up and Speak Out Summit that celebrates the voices of people with disabilities. You'll hear directly from disability self-advocates, families, speakers, and professionals as they share their voices on leadership, advocacy, and inclusion. This annual self-advocacy conference empowers people with disabilities to speak up for themselves, take action, and create positive change in their communities. Let's Speak Up. Let's Speak Out. Let's Be Heard. Join The Conversation

In this episode of our kid-focused Dungeons & Dragons adventure, our heroes have finally gained access to the inner vault! As they seek answers, they discover one member of the party has secrets yet to be uncovered... To find StoryGuider: Coloring Book Adventures for Kids Ages 2-7, visit Backerkit or TTRPGKids.itch.io! About us: When kids are at the table, everyone wins! Playing TTRPGs levels up kids' critical thinking, creativity, communication, collaboration, & confidence. That's why we create our kid-inclusive D&D show, tips for playing with kids, and campaigns to bring the adventures home! Our Kids' Adventures:  Our Website Support Our Work:  Patreon Follow Us: YouTube, Instagram, TikTok, Facebook   Shoutout to our incredible partners: Emberglow Gaming - GM Shield (affiliate, 10% off: TheKidsTable) Roll & Play Press - D&D Ideas (10% off affiliate link) The Shop of Many Things - Puzzle Box (30% off affiliate link) 1985 Games - Maps (10% off: KIDSTABLE) DnD Adventure Club - Kids' Adventures (10% off: KIDSTABLE10) Monument Studios - Music (30% off: KIDSTABLE) Mordenkatie's Magnificent Minis - PC Minis (10% off: KIDSTABLE) Trillium Rose Acres - Monster Minis (15% off: THEKIDSTABLE) Daily Hero Forge - PC Mini Design Ember Rest - Game Host   0:00 Recap 0:20 Episode 17 (Skip Intro) 18:05 Arc 6 Interlude: Where's Vee Been? #dungeonsanddragons #actualplay #familyfriendly

Alex Jordan may spend his nine-to-five building animatronics and puppets for places like Universal and Disney, but that's just the beginning of his welding story. After hours, Alex runs his own job shop, dives into 3D printing as a fabrication tool, and shares his knowledge through YouTube and social media. In this episode, we talk about how 3D printers can transform a weld shop, the craftsmanship behind theme park projects like Raptors and parade floats, and how Alex turned a simple county fair project into a 15-year career. We also get into his custom electric pit bike builds, the importance of teaching what you know, and how community events like maker gift exchanges are fueling the next generation of creators. This conversation is full of innovation, hustle, and inspiration — don't miss it!   Arc Junkies Podcast: Instagram: @Arcjunkiespodcast YouTube: https://www.youtube.com/@arcjunkiespodcast9253 Email: Show@arcjunkies.com LinkedIn: https://www.linkedin.com/in/jason-becker-45407b72?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base_contact_details%3BKipEwR3uQXCmCjaEfNzo6w%3D%3D Arc Junkies Website: https://arcjunkies.com Arc junkies Merch: https://shop.threadmob.com/arcjunkie/shop/home Underground Metal Works: https://www.underground-metalworks.com/   Friends of the Show: American Welding Society Conferences Pipeline Conference https://www.aws.org/community-and-events/conferences-and-events/pipeline/ Use ARCJUNKIES at Checkout and get a free gift at the event.   Outlaw Leather LLC Outlawleather.com Instagram: @outlawleatherusa Use ARCJUNKIES for 15% off all in-stock leather goods     Everlast Welders Instagram: @everlastwelders  YouTube: Everlast Welders         Online: https://bit.ly/37xJstI Use Codeword ARCJUNKIES at checkout to get upgraded to a free Nova Foot Pedal and TIG Torch with the purchase of any machine that comes with a stock foot pedal and TIG Torch. Fronius: Instagram: @FroniusUSA Website: Fronius.us ISOTUNES: Instagram: @isotunesaudio Online: https://shop.isotunes.com/arcjunkies10.  Use ARCJUNKIES10 at checkout and save $10 on your purchase    

Atlassian compra The Browser Company por 610 millones, apostando por Dia como navegador empresarial con IA mientras Arc queda en mantenimiento. Una startup que prometía revolucionar la navegación prioriza el camino corporativo sobre la innovación radical.Loop Infinito, podcast de Applesfera, de lunes a viernes a las 7.00 h (hora española peninsular). Presentado por Javier Lacort. Editado por Alberto de la Torre.Contacto:lacort@xataka.comX: @jlacort

Here it is! The Arc 7 Q&A! Spoilers for... you know, the show.LinksLink to the Not a Scratch YouTube ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@notascratch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Character Submission Form: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://forms.gle/1PNNXrNRMfbjHVSA6⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Maps Folder: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drive.google.com/drive/folders/1GbSB27GXliXbBKbKFeRjx1rjKEM3TWw0?usp=sharing⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/notascratch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website: www.notascratchcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AhdurinRegion Twitch: https://www.twitch.tv/theahdurinregion⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Podcast Twitter Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/NotAScratchCast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DM's Twitter Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/AhdurinRegion⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord link: https://discord.gg/kfhBdkTDnX⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AhdurinRegion YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UClRPG86yjATufmxvrgcfAVA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Muhammad/LumiShen YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC4QJYoKfnhEIr61eYflfkWg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Other Show: Ahdurin Region Sports: https://anchor.fm/ahdurin-region-sports⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Other Show: Ahdurin Talks Sports: https://anchor.fm/anirudh45⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The AhdurinCast Feed - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://theahdurincast.podbean.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Music by GlitchxCity: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/user/GlitchxCity/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Music by TableTop Audio: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tabletopaudio.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DM: AnirudhKyle: MuhammadRose: Daisy

Matty Dalrymple talks with Michael La Ronn about FROM BETA READERS TO BETTER STORY, including how authors can use alpha readers, beta readers, and ARC teams to strengthen their manuscripts and connect with their audience. They discuss when to bring in beta readers, how to choose the right people, and the differences between feedback from writers versus readers. Michael also shares strategies for paying beta readers, managing volunteer feedback, and using early input to improve both your story and your marketing.   Interview video at https://bit.ly/TIAPYTPlaylist Show notes at https://www.theindyauthor.com/episodes-all   If you find the information in this video useful, please consider supporting The Indy Author! https://www.patreon.com/theindyauthor https://www.buymeacoffee.com/mattydalrymple   Michael La Ronn has published many science fiction & fantasy books and self-help books for writers. He built a writing career publishing many books per year while raising a family, working a full-time job, and even attending law school classes in the evenings. Visit his fiction website at www.michaellaronn.com and his resources for writers at www.authorlevelup.com   Matty Dalrymple is the author of the Lizzy Ballard Thrillers, beginning with ROCK PAPER SCISSORS; the Ann Kinnear Suspense Novels, beginning with THE SENSE OF DEATH; and the Ann Kinnear Suspense Shorts. She is a member of International Thriller Writers and Sisters in Crime. Matty also writes, speaks, and consults on the writing craft and the publishing voyage, and shares what she's learned on THE INDY AUTHOR PODCAST. She has written books on the business of short fiction and podcasting for authors; her articles have appeared in "Writer's Digest" magazine. She serves as the Campaigns Manager for the Alliance of Independent Authors.

In this first episode of the Special Chronicles Podcast LIVE Coverage, host Daniel Smrokowski talks with Speaker, Comedian and Television Writer Zach Anner about his Keynote Presentation “Joyful Grit: Turning Setbacks Into Setups” and about his role as a television writer on the hit ABC sitcom “Speechless. We're excited to announce that Special Chronicles provided exclusive LIVE and On-Demand Coverage of the The Arc of Illinois #SUSO2025 – the annual Speak Up and Speak Out Summit that celebrates the voices of people with disabilities. You'll hear directly from disability self-advocates, families, speakers, and professionals as they share their voices on leadership, advocacy, and inclusion. This annual self-advocacy conference empowers people with disabilities to speak up for themselves, take action, and create positive change in their communities. Let's Speak Up. Let's Speak Out. Let's Be Heard. Join The Conversation

Wade shares updates on Ally Munitions' latest projects, from new 6mm ARC barrels and small batch rifle releases to upcoming ammo offerings. He also breaks down the buzz around potential suppressor legislation and what it could mean for shooters. Plus, talk on 22 ARC, 6.5 Creedmoor, and more.Stay connected: https://allymunitions.com

Show DescriptionChris is updating us on the progress of his CSS reset, thoughts on The Browser Company and Arc being bought by Atlassian, and in 2025 why would anyone build a website? Listen on WebsiteLinks Bend Old-Time Jams and Events Join or Die Join or Die on Netflix Bowling Alone - Wikipedia Microsoft CTO Kevin Scott on the Birth of the Agentic Web - The Verge Chris' CSS Starter

Emmet Kennedy is joined by Adam Mills (Total Performance Data), Jamie Wrenn, and on-course bookmaker Michael Cannon to review a pivotal weekend in Europe's racing calendar. The Arc trials at Paris Longchamp reshaped the betting market, while shocks at Kempton and in the Moulin raised serious questions.

On this week's episode, Brad and Eric explore all the fun stuff in 40k. You know, same as last week but different. Meanwhile, Berilio quickly rushes this editing, including this text description, so he can lay down in bed and Silk his Song. Just tell Brad the edit job was good, I bet he won't test listen to know anyway.   POORHAMMER MERCH! https://orchideight.com/collections/poorhammer PATREON: https://www.patreon.com/SolelySingleton YOUTUBE: https://www.youtube.com/@thepoorhammerpodcast TWITCH: https://www.twitch.tv/poorhammer Website: https://poorhammer.libsyn.com/   RELATED TO THIS EPISODE: Every SPACE MARINE model: https://www.youtube.com/watch?v=ZO6xJGBM5lY Every AELDARI model: https://www.youtube.com/watch?v=oEnL6f1dV3Y Every ADEPTUS MECHANICUS model: https://www.youtube.com/watch?v=IkEdNsHul9E   TIMESTAMPS: 00:00 Hello and Welcome 01:05 Intro 02:56 Space Marines (SM) 07:35 Adepta Sororitas (Sisters) 11:03 Adeptus Custodes (Custodes) 12:02 Grey Knights (GK) 13:21 Adeptus Mechanicus (AdMech) 16:22 Istra Gilitarum (IG) 17:29 Imperial Agents  18:14 Imperial Knights 20:31 Chaos Knights 20:49 Chaos Daemons 22:13 Chaos Space Marines, Thousand Sons and World Eaters 24:06 Emperor's Children 26:26 Death Guard 28:39 Aeldari 31:21 Drukhari 33:39 Ynnari 34:23 Leagues of Votann 37:13 Tyranids 38:44 Genestealer Cults 39:11 Life Here at Poorhammer 39:47 Orks 42:01 T'au Empire 45:08 Necrons 48:21 Final Thoughts 50:38 Alright Audio Audience Our Producers for AUGUST: 3D Frank A healthy ammount of piranhas airbrush video revenue that got lost in the couch Blizted_Brain BrokenReaper45 Corvus DemolitionMann Dixie Normous Drinking vodka and playing aerial gunlance just to feel something DrLace GilgameshVS iwonderhowlongittakesbeforbloodclawsaccepttheorgys Jan Geisse Jeric Foster Kiwifruitbird Le BloupBloup mistahsquiggems Mr Festastic #WheresMikesBaneblade n0rth the H3retic Nj harlan Off topic but where's the nearest Cracker Barrel, I'm eggin for a peggin ON MAH' WAY TA' STEAL A SNAZZWAGON! Pizza00100 Ratchet7989 thatmoiety The Idiot with grey knights VictorianBatman Wargame Simulator   Our Biggest Supporters: A certain grey baneblade A Pulsating Ball of Pure Energy A Suspicious Looking Guy Addoxin Adrian Franke Aetherion Collector of Slaaneshi thighs and regret Alex Fuja amdragon Amists Andreas Another hairy Sasquatch Ava Warrior Princess Ave Dominus Nuts Bigs The Purple Necron Blubbles 180 Bob Meyers Bobqer BRB gotta snazz my wagon Canuk-eh Carnuvex Chad the Frog Christopher Gargagliano Chroma Veil Colin. H Craig Judge Crazyshak48 Cube1359 Dairy Sorceror, addicted to mana potions Daniel Field5150 Darth Vergeance DasGoopy Dominick Colacicco Dylan Baker Edward Lawrence Enchantedgalaxycat Fay FlawlessOyster Freedom is only three edibles away Gathering Clouds GearOverlord Geete Hoss Hammond How are those rivets going Eric Hyena Beans HypnoticSpecter I read the Space Wolves Codex and all I got out of it was wolfwolfwolfwolfwolfwolfwolfwolf Illindi IrisHFoXRR isaac hall J3C GAM1NG James coe Jarrett DiPerna Jolyne Justin Yudichak kalex Kaydien moore Kentorb Kozak Krishna Chanamolu L'Etranger (Lukus) Lord of Chaos LSJay Madison Ramanama Malcador the Rizzler-ite Matthew Tsushima Michael Melcher Mitchell Mixolydius mmmm burnt toast Monkey218 morfiel55 Not-Gafie NotEE Omegashark Pierce forgot about changing their name as a bit for a while Protius7331 Qelan Rock roguetraderjake RossWarlock Rothana's All Terrain Tactical Enforcer Rymora saft SarahchaSauce Shaxxs pet otter Solonite Struggle_l3us The Mailman The Other Mailman Thecrusader13 TheFishboi Thrango

✈️ In this episode of the Special Chronicles Podcast's Unified at Work Series, host Daniel Smrokowski welcomes Samantha Alloway, Executive Director of The Arc of Illinois, for an inspiring conversation about the Wings for All program. Recorded following the August 16, 2025 Wings for All event at Chicago O'Hare International Airport (ORD) in partneship with United Airlines' Bridge Disability Business Resource Group, this episode dives into: What Wings for All is and why it matters for travelers with autism and intellectual/developmental disabilities (IDD). Behind-the-scenes stories from the event at O'Hare. Heartwarming family moments, including a child who overcame fears to board an aircraft for the first time. The importance of inclusion in airports, workplaces, schools, and communities.

Join Maddy Playle, Chris Cook and Liam Headd to discuss a lively week in racing, including Arc trials' day at Longchamp on Sunday.  Last year's runner-up Aventure shot to favouritism for the French showpiece after winning the Prix Vermeille, with Whirl's defeat the second notable disappointment for the race after Kalpana's loss to Giavellotto in the September Stakes at Kempton. The team also review comments by John Gosden and Aidan O'Brien regarding Ombudsman and Delacroix in the Irish Champion Stakes, with the Ballydoyle maestro suggesting the British trainer was a sore loser after ruling out Godolphin's colt from the Group 1 clash. Finally, the panel ponder how effective Wednesday's strike action will be as racing figures prepare to gather in Westminster.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Episode 182 - Every Faction's Afterlife   In this week's episode, Brad and Eric explore all the fun stuff in 40k. You know, same as last week but different. Meanwhile, Berilio quickly rushes this editing, including this text description, so he can lay down in bed and Silk his Song. Just tell Brad the edit job was good, I bet he won't test listen to know anyway.   POORHAMMER MERCH! https://orchideight.com/collections/poorhammer PATREON: https://www.patreon.com/SolelySingleton YOUTUBE: https://www.youtube.com/@thepoorhammerpodcast TWITCH: https://www.twitch.tv/poorhammer Website: https://poorhammer.libsyn.com/   RELATED TO THIS EPISODE: Every SPACE MARINE model: https://www.youtube.com/watch?v=ZO6xJGBM5lY Every AELDARI model: https://www.youtube.com/watch?v=oEnL6f1dV3Y Every ADEPTUS MECHANICUS model: https://www.youtube.com/watch?v=IkEdNsHul9E   TIMESTAMPS: 00:00 Hello and Welcome 01:05 Intro 02:56 Space Marines (SM) 07:35 Adepta Sororitas (Sisters) 11:03 Adeptus Custodes (Custodes) 12:02 Grey Knights (GK) 13:21 Adeptus Mechanicus (AdMech) 16:22 Istra Gilitarum (IG) 17:29 Imperial Agents  18:14 Imperial Knights 20:31 Chaos Knights 20:49 Chaos Daemons 22:13 Chaos Space Marines, Thousand Sons and World Eaters 24:06 Emperor's Children 26:26 Death Guard 28:39 Aeldari 31:21 Drukhari 33:39 Ynnari 34:23 Leagues of Votann 37:13 Tyranids 38:44 Genestealer Cults 39:11 Life Here at Poorhammer 39:47 Orks 42:01 T'au Empire 45:08 Necrons 48:21 Final Thoughts 50:38 Alright Audio Audience Our Producers for AUGUST: 3D Frank A healthy ammount of piranhas airbrush video revenue that got lost in the couch Blizted_Brain BrokenReaper45 Corvus DemolitionMann Dixie Normous Drinking vodka and playing aerial gunlance just to feel something DrLace GilgameshVS iwonderhowlongittakesbeforbloodclawsaccepttheorgys Jan Geisse Jeric Foster Kiwifruitbird Le BloupBloup mistahsquiggems Mr Festastic #WheresMikesBaneblade n0rth the H3retic Nj harlan Off topic but where's the nearest Cracker Barrel, I'm eggin for a peggin ON MAH' WAY TA' STEAL A SNAZZWAGON! Pizza00100 Ratchet7989 thatmoiety The Idiot with grey knights VictorianBatman Wargame Simulator   Our Biggest Supporters: A certain grey baneblade A Pulsating Ball of Pure Energy A Suspicious Looking Guy Addoxin Adrian Franke Aetherion Collector of Slaaneshi thighs and regret Alex Fuja amdragon Amists Andreas Another hairy Sasquatch Ava Warrior Princess Ave Dominus Nuts Bigs The Purple Necron Blubbles 180 Bob Meyers Bobqer BRB gotta snazz my wagon Canuk-eh Carnuvex Chad the Frog Christopher Gargagliano Chroma Veil Colin. H Craig Judge Crazyshak48 Cube1359 Dairy Sorceror, addicted to mana potions Daniel Field5150 Darth Vergeance DasGoopy Dominick Colacicco Dylan Baker Edward Lawrence Enchantedgalaxycat Fay FlawlessOyster Freedom is only three edibles away Gathering Clouds GearOverlord Geete Hoss Hammond How are those rivets going Eric Hyena Beans HypnoticSpecter I read the Space Wolves Codex and all I got out of it was wolfwolfwolfwolfwolfwolfwolfwolf Illindi IrisHFoXRR isaac hall J3C GAM1NG James coe Jarrett DiPerna Jolyne Justin Yudichak kalex Kaydien moore Kentorb Kozak Krishna Chanamolu L'Etranger (Lukus) Lord of Chaos LSJay Madison Ramanama Malcador the Rizzler-ite Matthew Tsushima Michael Melcher Mitchell Mixolydius mmmm burnt toast Monkey218 morfiel55 Not-Gafie NotEE Omegashark Pierce forgot about changing their name as a bit for a while Protius7331 Qelan Rock roguetraderjake RossWarlock Rothana's All Terrain Tactical Enforcer Rymora saft SarahchaSauce Shaxxs pet otter Solonite Struggle_l3us The Mailman The Other Mailman Thecrusader13 TheFishboi Thrango

In today's MadTech Daily, we discuss the Arc browser maker being acquired, Apple preparing a Siri search tool, OpenAI launching an AI hiring platform, and smartphones pushing streaming past linear TV in Germany.

Listen to weekly sermons from Velocity Church in Lawrence, KS. Velocity is a vision-fueled and faith-filled community changing lives and transforming a city with the message of Jesus. For more information visit www.findvelocity.org

We're kicking-off Season 20 with Arc of Infinity! This story features Time Lords doing what Time Lords do best, the return of Omega and introduction of his mutant turkey/pterodactyl thing, and some traipsing around Amsterdam. It sounds like it should be quite good. But will the Watchers think that it's the sort of bang that the season should start with – one that caused by anti-matter and matter colliding?   Join us as we discuss our total disdain for the planet Gallifrey and Time Lord society, our love of Action Hero Nyssa, the brain slugs from Futurama, how the Castellan and Commander Maxil seem to be aware of the narrative structure of a Doctor Who story, and how President Borusa is apparently very susceptible to phishing. We also delve into the question of “what is the Matrix?” – because the last time we saw it, it certainly wasn't… whatever the heck we see in this story.   If you would like to watch along with us, you can find this story available for streaming on Britbox in the USA (http://www.britbox.com) and BBC iPlayer in the UK (https://bbc.in/48GSaCB). If you're a little old fashioned and prefer physical media (like our very own Anthony), you can also find it on the Doctor Who Season 20 Blu Ray box set from Amazon US (https://amzn.to/3VyxIPe) and Amazon UK (https://amzn.to/3V2IL34)   Other media mentioned in this episode*: Blake's 7 – The Complete Collection (Amazon US: https://amzn.to/2Zh7045 | Amazon UK: https://amzn.to/39luyGI) The Tripods (Amazon US: https://amzn.to/40Omomf | Amazon UK: https://amzn.to/4ft5w8z) Tenko (Amazon US: https://amzn.to/44vCOzm | Amazon UK: https://amzn.to/3wtYY8D) Z Cars: Complete Collection One & Two (Amazon US: https://amzn.to/3pdDtmF | Amazon UK: https://amzn.to/3lV2cKn) Juliet Bravo: Series 1 (Amazon US: https://amzn.to/3GOLfyc | Amazon UK: https://amzn.to/4iZgvb9) The West Wing (Amazon US: https://amzn.to/46mlIGI | Amazon UK: https://amzn.to/465XhMC) Batman and Robin (Amazon US: https://amzn.to/3I85GHj | Amazon UK: https://amzn.to/4nhPwu3) Batman Forever (Amazon US: https://amzn.to/4n6Iok2 | Amazon UK: https://amzn.to/4miqied) Futurama – Seasons 1-8 (Amazon US: https://amzn.to/3jfbkaQ | Amazon UK: https://amzn.to/3aQeMUL) All Creatures Great and Small: The Complete Collection (Amazon US: https://amzn.to/3FpbQ1J | Amazon UK: https://amzn.to/3iC2xm9) The Great North (USA – Hulu: http://www.hulu.com | UK – Disney+: http://www.disneyplus.co.uk) Dark Souls (Amazon US: https://amzn.to/45OlkRo | Amazon UK: https://amzn.to/3K2p60K) Metroid Prime Remastered (Amazon US: https://amzn.to/4ndcWAE | Amazon UK: https://amzn.to/46msgVW) Neo Pets (https://www.neopets.com)    Finally, you can also follow us and interact with us on Facebook and Instagram. You can also e-mail us at watchers4d@gmail.com, and you can join us on our Discord server. If you're enjoying this podcast, please subscribe to the show, and leave us a rating or review.   *Support Watchers in the Fourth Dimension! We are an Amazon affiliate and earn a small commission from purchases through Amazon links. This goes towards the running costs of the podcast.

"The Art of Subtraction" | Pastor Hood | 9.7.25 by ARC of Carson City, NV

Its Saturday Its very Special and we are down a couple of members but don't worry or Arc ambassador stepped in to help us out. Listen in to see what we got into...Check us out on all social media at time for another podcast or check out our website at timeforanother.com Send us an email at timeforanotherpodcast@gmail.comSupport this podcast at — https://redcircle.com/time-for-another/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This week we are lucky enough to be reviewing an ARC that we received by Gena Showalter and her publisher Montlake! So thank you for this opportunity to read and give our honest review.  We hope you enjoyed this episode and if you did don't forget to rate us as it helps push this podcast our to more great listeners like you! Make sure you follow us on all our socials here!

Charlotte Greenway brings you the Saturday Edition and starts by look at Saturday's Sprint Cup from Haydock with inout from trainer's Jerome Reynier and James Fanshawe on favourite Lazzat and fellow Wathnan owned Kind of Blue. Then onto France where Rosallion is looking to bag his first group 1 of the season in the Moulin and his trainer Richard Hannon explains the decision to send his colt here, having not been part of the original plan and finally Ed Walker shares his hopes for Almaqam in one of three competitive Arc trials on Sunday.

From his early days with Lodgic and World Trade, his first involvements with Yes and Chris Squire (in Conspiracy), through his solo career, many side projects (The Prog Collective, Circa, Yoso, and Arc of Life), and his eventual return to the Yes fold, Billy Sherwood has sure been around the proverbial block! Join me on […]

The Rhino in the room can't be ignored: after decades in the vault, Buckingham Nicks is finally getting a reissue. eCoustics Editors Eric Pye, Jeremy Sikora, and producer Mitch Anderson team up with mastering engineer Kevin Gray (Cohearent Audio) to dig into why this cult classic vanished, why it's back now, and what it means for fans who've been chasing scratched LPs for years. Along the way, we get into the bigger picture—the state of the reissue market, the future of vinyl cutting, and why Fleetwood Mac drama still drives the mythology around this record. Chaos may have fueled the Mac, but this one's all about clarity.Thank you to Bowers & Wilkins and SVS for their support of our programming!www.svsound.comwww.bowerswilkins.comCredits:• Original intro music by The Arc of All. https://sourceoflightandpower.bandcamp.com• Voice Over Provided by Todd Harrell of SSP Unlimited. https://sspunlimited.com• Production by Mitch Anderson, Black Circle Studios. https://blackcircleradio.comDon't forget to check our website for daily updates on the latest electronics, news, recommendations, and deals on high-end audio, loudspeakers, earphones, TVs, and more.www.ecoustics.com#fleetwoodmac #ecoustics #audiophilereissue #vinylreissue #buckinghamnicks #rhinorecords #kevingray #cohearentaudio #vinylcommunity #classicalbums #hifi #audiophile #vinylmastering #recordindustry #musicindustry

Emmet Kennedy, Andy Newton, George Gorman and Peter Michael return after another huge weekend of winners (20/1, 16/1, 14/1, 7/2, 6/4) with your betting guide to Saturday's live ITV Racing from Haydock, Ascot and Kempton.

"Search for Truth 64" | Pastor Evan Hood | 9.3.25 by ARC of Carson City, NV

“Sonaspection has been keeping inspectors honest since 1980—by making flaws on purpose. This week, Jeremy Ring joins me to talk NDT, mentorship, and how controlled cracks build better inspectors.”   This week on the Arc Junkies Podcast, I'm joined by Jeremy Ring, President of Sonaspection. If you're not familiar with Sonaspection, they've been training inspectors since 1980 by creating controlled flaws in real welded samples. Their work keeps inspectors sharp, welders accountable, and industries safe. Jeremy shares his journey from NASCAR engineering to NDT leadership, and we dig into how flawed specimens help inspectors build the confidence to make the right call in the field. We also talk about mentorship, the future of inspection with AI, the global shortage of inspectors, and why proper training is critical to preventing failures that could put lives at risk. If you've ever wondered how inspectors sharpen their skills—or why “known flaws” are the best teachers—this is an episode you don't want to miss.   Arc Junkies Podcast: Instagram: @Arcjunkiespodcast YouTube: https://www.youtube.com/@arcjunkiespodcast9253 Email: Show@arcjunkies.com LinkedIn: https://www.linkedin.com/in/jason-becker-45407b72?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base_contact_details%3BKipEwR3uQXCmCjaEfNzo6w%3D%3D Arc Junkies Website: https://arcjunkies.com Arc junkies Merch: https://shop.threadmob.com/arcjunkie/shop/home Underground Metal Works: https://www.underground-metalworks.com/   Friends of the Show: American Welding Society Conferences Pipeline Conference https://www.aws.org/community-and-events/conferences-and-events/pipeline/ Use ARCJUNKIES at Checkout and get a free gift at the event.   Outlaw Leather LLC Outlawleather.com Instagram: @outlawleatherusa Use ARCJUNKIES for 15% off all in-stock leather goods     Everlast Welders Instagram: @everlastwelders  YouTube: Everlast Welders         Online: https://bit.ly/37xJstI Use Codeword ARCJUNKIES at checkout to get upgraded to a free Nova Foot Pedal and TIG Torch with the purchase of any machine that comes with a stock foot pedal and TIG Torch. ISOTUNES: Instagram: @isotunesaudio Online: https://shop.isotunes.com/arcjunkies10.  Use ARCJUNKIES10 at checkout and save $10 on your purchase